Levi & Korsinsky notifies investors that it has commenced an investigation into Bruker Corporation (NASDAQ: BRKR) concerning potential violations of the federal securities laws.
On July 21, 2025, Bruker announced disappointing preliminary results for the second quarter, ended June 30, 2025. The Company disclosed earnings and revenue that both fell well-below expectations and announced an estimated 7% year-over-year organic revenue decline, significantly worse than management previously forecast. Bruker blamed soft demand from academic institutions and a slowdown in biopharma for the weakness in bookings, despite having last quarter “established a floor based on current headwinds” including concerns around academic uncertainty and the threat of biopharma tariffs. Following this news, Bruker’s stock price fell by $3.74 per share to open at $36.82 per share.
If you suffered a loss on your Bruker Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





